Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Current Leases for 8 consecutive years, with $12.0 million as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 671.78% year-over-year to $12.0 million; the TTM value through Mar 2026 reached $12.0 million, up 671.78%, while the annual FY2025 figure was $11.9 million, 2.99% up from the prior year.
  • Current Leases hit $12.0 million in Q1 2026 for Kymera Therapeutics, up from $11.9 million in the prior quarter.
  • Across five years, Current Leases topped out at $12.0 million in Q1 2026 and bottomed at $1.1 million in Q3 2022.
  • Average Current Leases over 5 years is $5.4 million, with a median of $2.6 million recorded in 2023.
  • Year-over-year, Current Leases skyrocketed 828.03% in 2024 and then tumbled 83.37% in 2025.
  • Kymera Therapeutics' Current Leases stood at $1.4 million in 2022, then skyrocketed by 259.94% to $5.1 million in 2023, then surged by 128.77% to $11.6 million in 2024, then rose by 2.99% to $11.9 million in 2025, then grew by 0.76% to $12.0 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $12.0 million, $11.9 million, and $11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.